Chronic neutrophilic leukemia medical therapy: Difference between revisions
Homa Najafi (talk | contribs) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chronic neutrophilic leukemia}} | {{Chronic neutrophilic leukemia}} | ||
{{CMG}}; {{AE}}{{Homa}} | {{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
There is no standard medical treatment for chronic neutrophilic leukemia (CNL). Although, [[Hydroxyurea]], [[Ruxolitinib]], [[Interferon]], [[Thalidomide]], [[Cladribine]] and [[Imatinib]] are some options that are used in [[patients]] with CNL. | There is no standard medical treatment for chronic neutrophilic leukemia (CNL). Although, [[Hydroxyurea]], [[Ruxolitinib]], [[Interferon]], [[Thalidomide]], [[Cladribine]] and [[Imatinib]] are some options that are used in [[patients]] with CNL. | ||
Revision as of 12:59, 11 April 2019
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia medical therapy |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
There is no standard medical treatment for chronic neutrophilic leukemia (CNL). Although, Hydroxyurea, Ruxolitinib, Interferon, Thalidomide, Cladribine and Imatinib are some options that are used in patients with CNL.
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia medical therapy |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia medical therapy |
Medical Therapy
There is no established treatment for patients with CNL. However, following options may be useful in treatment of patients with CNL:[1][2][3]
- Preffered ones:
- 1. Hydroxyurea:[1][4][5]
- Preferred regimen: 20-30 mg/kg PO as a single dose daily, for 6 weeks
- Note (1): Hydroxyurea is the most effective drug in controlling of leukocytosis and splenomegaly
- Note (2): Hydroxyurea is used before progressive or blast transformation stages
- 2. Ruxolitinib : Based on the role of Ruxolitinib on JAK-STAT pathway and this pathway is also had role in pathogenesis of CNL, it can be used in treatment of patients with CNL.[2][6]
- Preferred regimen in myeloproliferative disorders based on platelet count:
- Greater than 200×109/L: 20 mg PO q12h
- 100 to 200×109/L: 15 mg PO q12h
- 50 to less than 100×109/L: 5 mg PO q12h
- Note (1) : Monitoring of complete blood counts every 2 to 4 weeks should be done until doses are stabilized.
- Preferred regimen in myeloproliferative disorders based on platelet count:
- 1. Hydroxyurea:[1][4][5]
- Alternative ones:
- 1.Interferon : IFN-α is used in some patients but the result of responding to this drug was not equal.[7]
- 2.Thalidomide
- 3.Cladribine
- 4.Imatinib
References
- ↑ 1.0 1.1 Elliott, M A; Hanson, C A; Dewald, G W; Smoley, S A; Lasho, T L; Tefferi, A (2004). "WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature". Leukemia. 19 (2): 313–317. doi:10.1038/sj.leu.2403562. ISSN 0887-6924.
- ↑ 2.0 2.1 Szuber, Natasha; Tefferi, Ayalew (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer Journal. 8 (2). doi:10.1038/s41408-018-0049-8. ISSN 2044-5385.
- ↑ You W, Weisbrot IM (1979). "Chronic neutrophilic leukemia. Report of two cases and review of the literature". Am J Clin Pathol. 72 (2): 233–42. PMID 289288.
- ↑ Elliott, Michelle A.; Pardanani, Animesh; Hanson, Curtis A.; Lasho, Terra L.; Finke, Christy M.; Belachew, Alem A.; Tefferi, Ayalew (2015). "ASXL1mutations are frequent and prognostically detrimental inCSF3R-mutated chronic neutrophilic leukemia". American Journal of Hematology. 90 (7): 653–656. doi:10.1002/ajh.24031. ISSN 0361-8609.
- ↑ "Hydrea (Hydroxyurea Package Insert)" (PDF).
- ↑ Leah Wolfe (2016). "Ruxolitinib in Myelofibrosis and Polycythemia Vera". Journal of the advanced practitioner in oncology. 7 (4): 436–444. PMID 29226001. Unknown parameter
|month=ignored (help) - ↑ M. A. Elliott, G. W. Dewald, A. Tefferi & C. A. Hanson (2001). "Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study". Leukemia. 15 (1): 35–40. PMID 11243396. Unknown parameter
|month=ignored (help)